John Ellis's most recent trade in InnovAge Holding Corp was a trade of 25,316 Common Stock, $0.001 par value done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| InnovAge Holding Corp | John Ellis Bush | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 25,316 | 45,157 | - | 0 | Common Stock, $0.001 par value | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 18,589 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 10,000 | 64,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 14 Apr 2025 | 10,000 | 12,000 (0%) | 0% | 35 | 350,000 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 14 Apr 2025 | 10,000 | 22,000 (0%) | 0% | 8.5 | 84,500 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 30,000 | 74,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Sale of securities on an exchange or to another person at price $ 34.05 per share. | 01 Apr 2025 | 30,000 | 12,000 (0%) | 0% | 34.1 | 1,021,500 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 01 Apr 2025 | 30,000 | 42,000 (0%) | 0% | 8.5 | 253,500 | Common Stock |
| InnovAge Holding Corp | John Ellis Bush | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 19,841 | 19,841 | - | 0 | Common Stock, $0.001 par value | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| 2U Inc | John B. Ellis | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.50 per share. | 01 Apr 2022 | 972 | 42,444 (0%) | 0% | 13.5 | 13,122 | Common Stock |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.68 per share. | 16 Mar 2022 | 479 | 43,416 (0%) | 0% | 11.7 | 5,595 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Purchase of securities on an exchange or from another person at price $ 8.39 per share. | 15 Mar 2022 | 12,000 | 12,000 (0%) | 0% | 8.4 | 100,680 | Common Stock |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 14,470 | 42,454 (0%) | 0% | 0 | Common Stock | |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 1,441 | 43,895 (0%) | 0% | 0 | Common Stock | |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.93 per share. | 03 Jan 2022 | 1,271 | 27,984 (0%) | 0% | 20.9 | 26,602 | Common Stock |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 7,174 | 31,749 (0%) | 0% | 0 | Common Stock | |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.34 per share. | 01 Oct 2021 | 2,494 | 29,255 (0%) | 0% | 34.3 | 85,644 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 49,869 | 49,869 | - | - | Stock Option (right to buy) | |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.39 per share. | 01 Jul 2021 | 106 | 24,575 (0%) | 0% | 41.4 | 4,387 | Common Stock |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.49 per share. | 01 Apr 2021 | 571 | 24,681 (0%) | 0% | 40.5 | 23,120 | Common Stock |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 3,838 | 25,252 (0%) | 0% | 0 | Common Stock | |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2021 | 5,948 | 24,565 (0%) | 0% | 0 | Common Stock | |
| 2U Inc | John B. Ellis | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.10 per share. | 01 Jan 2021 | 3,151 | 21,414 (0%) | 0% | 39.1 | 123,204 | Common Stock |
| Hycroft Mining Holding Cor... | John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2020 | 10,095 | 10,095 | - | - | Restricted Stock Units | |
| Hycroft Mining Holding Cor... | John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2020 | 6,730 | 6,730 | - | - | Restricted Stock Units |